

# Cancer cell line for mechanisms of clinical anticancer drug resistance

Name : Tulsi Asalalia

Enrollment ID : 19SS03MB002

## ABSTRACT

Anticancer medications opposition is an unpredictable interaction that emerges from modifying in the medication targets. Advances in the DNA microarray, proteomics innovation and the improvement of designated treatments give the new techniques to beat the medication obstruction. Albeit a plan of the new chemotherapy specialists is developing rapidly, compelling chemotherapy specialist has not been found against the high level phase of malignancy. The cancer cell opposition against the anticancer specialists can be because of numerous elements like the person's hereditary contrasts, particularly in tumoral physical cells. Cancer drug resistance is obtained, the medication obstruction can be happened by various instruments, including multi-drug obstruction, cell passing repressing, adjusting in the medication digestion, epigenetic and drug targets, upgrading DNA repair and gene amplification. We illustrated the instruments of cancer drug obstruction and the therapy failure by normal chemotherapy specialists in the diverse sort of tumors. Chemotherapy is one of the pillars of clinical cancer treatment. In the cancer research, cancer biological qualities is refreshing each day. Cancer causes the uncontrolled development of strange cells and dynamic modifying in the genome (which cause cancerous features in normal cells).

**KEYWORDS** : Cancer, Chemotherapy, Drug resistance, Multidrug resistance protein, Cell line, Chemoresistance, Mechanisms, Clinical use.

## INTRODUCTION

Several types of cancer are initially capable for chemotherapy, but during treatment - patients may develop resistance to therapy. Total 110 drug resistant cell lines, from lung tumors and leukemias have been developed. It has been observed that the drugs used for induction of resistance represented the drugs used for first-line treatment of each neoplasia. Acquisition of drug resistance is a major clinical problem in antineoplastic treatment, the present work aimed to present, through a literature review, the development of chemoresistant cells lines as a model in experimental oncology. In vitro models have been a cornerstone of anti-cancer drug development, their direct relevancy to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance transcriptome of six cancer types, in established cancer cell lines such as grown in monolayer, xenograft, 3D scaffold micro dissected, clinical samples, mostly containing >75% tumor cells. Normal tissue controls the production and release of growth promoting signals that regulate the induct and develop the cell cycle. Cancer cells shows deregulation of signals and may obtain the ability to maintain continuous and abnormal burst signaling, inhibition of growth suppressors, replicative immortality, resistance to cell death, angiogenesis and metastasis that leads to an inadequate and pathogenic functioning of the tissue. It may obtain as a cellular response to drug exposure or innate subpopulation of heterogeneous cancer cells. Principle mechanisms includes altered membrane transport involving the p-glycoprotein product of the multidrug resistance (MDR) gene or other associated proteins, increased drug degradation due to altered expression of drug metabolizing enzymes altered target enzyme, decreased drug activation, sub cellular

redistribution, drug interaction, enhanced DNA repair and failure to apoptosis as a result of mutated cell cycle proteins such as p21.

In addition to, normal cancer therapies procedure such as, radiation treatment, chemotherapy, blend treatment and laser treatment (Longley DB, 2005). the particular treatments depend on the better origination of the science and atomic hereditary qualities in the tumor movement utilized for the promising treatments. 90% of failures in the chemotherapy are during the invasion and metastasis of cancers related to drug resistance. In the chemotherapy, by following the administration of a certain drug, a large number of patient tumor cells become resistant to the drug so the drug resistance appears as a serious problem in the field of cancer( Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ,1946). The cancer treatments by studying the tumor suppressor genes molecular targets of oncogenes, and RNA interference are expanded (Nabholtz JM, 2001).

Different purposes of these therapy includes :

1. The kinases inhibition that involved in the cell proliferation
2. Improving the rapid immune responses in cancer
3. Specializing the medications
4. Drug delivery into cancer cells
5. Reducing the side effects of anticancer drugs, etc (RJ, 2006)

There are a few mechanisms including inactivation of the medication, multi-drug opposition, changes in drug digestion, restraining cell passing epigenetic and drug targets, quality intensification that cause the protection from the chemotherapy and upgrade DNA repair.




Figure 1: The mechanism of drug resistance in the cancer cell. Cancer cells will become resistant to drugs by the mechanisms such as the inactivation of the drug, multi-drug resistance, cell death inhibition, altering in the drug metabolism, epigenetic changing, changes in the drug targets, enhances DNA-repair and target gene amplification.

## Application of cell line

Experimental oncology is defined as the study of analysis and understanding of carcinogenesis, sometimes induced experimental animal models with the use of physical, chemical, natural carcinogens or biological agents. Experimental oncology supports clinical oncology, by studying oncolytic effects of artificial (drug) or natural (hormones) chemicals in tissue or cell cultures (RMP, 1889-1945). National Cancer Institute (NCI) of the United States of America established an evaluating program for antitumor particles, now, a murine cell line P388 was applied to contemplate the components, tumor science and cancer-causing changes in tumors of human beginning. Another in vitro essential screening was created dependent on a board of various tumor cell lines got from human biopsies (Shoemaker RH, 2002). This panel contained around 60 diverse cell lines got from tumor biopsy examples from patients with strong tumors and hematological cancers, and was named NCI-60. This panel encouraged a number of research programs, particularly those related to cytotoxic chemotherapy and to the discovery of drugs.

Hematologic cancer, consists of leukemia, lymphoma, and myeloma, start and progress in essential or auxiliary lymphoid organs and create and spread differently from solid tumors (Curran EK, 2017). The principle normal for these kinds of malignancy is their capacity to influence bone marrow hematopoietic antecedents that, all along, are not, at this point confined to a solitary district of the body, showing themselves in a few sections without regarding anatomical barriers (neoplasms, 2016).




Figure :1 Mechanism that can active resistance of cancer cell to chemotherapeutic agents.




Figure 2: Establishment of a drug-resistant cell lines with increasing concentrations of a certain drug to study the biological changes leading to resistance mechanisms.

## Establishment of drug resistance cell-line

Studies on the mechanisms of cytotoxicity and resistance to chemotherapy in experimental oncology are based on the development and analysis of resistant cancer cell lines (McDermott M, 2014). MDR is considered a multifactorial phenomenon and occurs mainly as a result of hyperexpression of transporters of the superfamily of ATP binding cassette proteins (ABC transporters) (J., 2016), a large family of proteins that uses the energy of hydrolysis of ATP to actively expel the drug out of cells (CH, 2005). Thus, many current studies concentrate on trying to suppress MDR, for a more effective therapy against cancer.

Cell lines created as models of opposition, especially through the organization of a specific chemotherapeutic medication that is usually utilized in clinical practice, are utilized to examine and comprehend MDR to foster procedures to conquer it. So that described chemoresistant cell lines, and parental cell line, should be created (Shi Z, 2007) (Okamura T, 2013).

Thus, this work to recognize strong and hematopoietic tumor models of chemoresistant cell lines, which have been created to understand the phenomenon of resistance to chemotherapeutic, ordinarily seen as a model of development in cancer and as tool for the revelation of new drug which might be more effective against disease (Longley DB, 2005).

## INTRINSIC AND EXTRINSIC FACTORS IN DRUG RESISTANCE

### Tumor heterogeneity

Intra-tumor heterogeneity can be seen at various cancer levels and might be assignable to various components that primarily happen at the cellular level. This implies, the regular age of variations structure which are considered by different hereditary, epigenetic, transcriptomic and proteomic properties. The genotypic changes include: transformations, quality enhancements, erasures, chromosomal modifications, rendering of the hereditary components, movements and micro RNA adjustment. Genomic unsteadiness produces an incredible degree of intercellular hereditary heterogeneity in cancer (Nathanson DA, 2014). Epigenetic factors including mi RNA, transcriptomic and proteomic heterogeneity may ascend because of essential genotypic varieties, however can likewise reflect cell cycle stage, stochastic varieties between cells, or various leveled association of cells as per the malignant growth foundational microorganism hypothesis. These known as intrinsic factors cause tumor heterogeneity. Extrinsic factors include pH, hypoxia, and paracrine signaling interactions with stromal and other tumor cells (SE, 1991) (VK, 2013). These components change, increment, or reduce quality items which directly associated with the age of drug resistance. (Gatenby RA, 2010) (Junttila MR, 2013)

### Cancer stem cell

Cancer stem cell population have been identified in different hematopoietic and strong tumors, and may be the cell of beginning of hematopoietic and strong tumors. In spite of the fact that chemotherapy impairs a huge number of cells in a tumor, however it is perceived that the chemotherapy specialists are taken out from malignancy immature microorganisms with the uncommon instruments, which may be a significant for drug opposition, for example, over expression of the ATP-restricting tape (ABC), drug carriers like ABCB1, which encodes P-glycoprotein, and the ABCG2, which was initially distinguished in mitoxantrone safe cells have been displayed to keep disease undifferentiated organisms from chemotherapeutic specialists. (Dean M, 2005) Cancer stem cell growth immature microorganisms provides few of typical undeveloped cells that accommodates a long lifetime, including the relative quiet, protection from medications and poisons through the statement of medication efflux carriers, a functioning DNA-fix limit and a protection from apoptosis, vascular specialty, torpidity, hypoxic solidness and improve action of fix enzymes (Pal B, 2016). So, the identifying and eliminating these small populations of cancer cells is such a significant help to eliminate the drug resistance. (J, 2016)

### Inactivation of the anticancer drug

The anticancer drugs efficiency and activity are dependence on the complex mechanisms. The connection among drugs and various type of proteins (in vivo) can change the characteristics of drug and eventually enact them. Cancer cells become resistance by reducing the movement of drugs. The intense myeloid leukemia (AML) therapy with cytarabine (AraC) (an enemy of disease drug nucleotide after various phosphorylations can be changed over to cytarabine triphosphate (AraC-triphosphate) is an illustration of this specific circumstance. AraC has no impact on the malignant growth cells at the initial step, however its phosphorylated structure is deadly to cells and harms them (Zahreddine H, 2013). Down-guideline or changes in the proteins and catalysts including in this pathway (phosphorylation responses) diminish the AraC action and it causes drug-safe disease cells to AraC (Michael M, 2005).

Another example of anti cancer drug is **glutathione S-transferase family (GST)** that has three huge super families- **cytosolic, mitochondrial and microsomal-additionally**, known as **MAPEG proteins**. This gathering of the catalyst has a significant part in the detoxification of medications, ionizing particles and electron compounds in the phone. GST compounds increment the medication obstruction in disease cells straight by the detoxification of hostile to malignant growth drug or in a roundabout way by the mitogen-

activated protein kinase (MAPK) pathway hindrance in the RAS-MAPK way. The expanded articulation of GST in the disease cells and follow the expanding levels in the detoxification of anticancer medications, decrease the harms and lethality of these medications on the malignancy cells. It is related with expanding the protection from apoptosis, initiated by different improvements.

Multi-drug resistance (MDR) in the cancer chemotherapy has been bought up as the capacity of cancer cells to survive against a wide range of anti-cancer drugs (Zahreddine H, 2013). MDR mechanism may be developed by increased release of the drug outside the cells. So the drug assimilation is diminished in these cell (Sampath D, 2006).

### Changing the drug metabolism

Chemotherapeutic specialist digestion systems can be happened by catalysts. Chemicals are the main variables for deciding the specialist fixation, the inward and external of the cells. Responses to the specialists like oxidation, decrease and hydrolysis which are known as stage I responses, and the utilization and change which are known as a stage II responses assume a significant part in ensuring ordinary cells against harmful specialists. These reactions reduce the drug resistance in the cancer cells via two manners including 1) reducing the activation of pro-drugs (reduced the activity of some enzymes) and 2) increasing the drug inactivation (increased activity of some enzymes). One of the important examples in the phase I reactions which managed with cells is the detoxification done by cytochrome P450 (Longo-Sorbello GS, 2001). The phase II response of the drug which was changed over to glucuronic corrosive, sulfate and glutathione, these diminish the medication movement and discard its electrophilic toxicity (JM., 2016). Increasing the creation of glutathione and the detoxification happened by glutathione transferases which assume a significant part in the protection from numerous alkylating specialists and platinum-based anticancer medications, for example, cisplatin and doxorubicin (JM., 2016).

### Changing the chemotherapeutic target

The impact of chemotherapeutic specialists might have been relied upon the alterations, for example, the transformations and changes in the expression level of their objectives. These type of changes in the specialist targets will prompt drug resistance (Jones D, 2009). The topoisomerase catalysts are liable for opening the compaction in the construction of DNA during the replication (Simon JA, 2013) (S, 2014). Doxorubicin, predominantly utilized for the therapy of the strong tumors, begins from anthracycline organism anti-toxin could hinder Topoisomerase II. Cancer cells with the transformations in topoisomerase II modify the reason for the referenced drug.(table 1) In a BCR-ABL translocation, involving the different parts of the two genes depending on which chromosomal break points situation. The drug resistance processes are multifactorial. The point mutations and amino acid substitution in the kinase domain of BCR-ABL lead to altered structure in the proteins and prevent the proper binding of the drugs. Approximately 70 different types of the mutations have been reported in the kinase domain of BCR-ABL. (table 1)

### Enhancing the DNA repair

DNA fix is one of the instruments of the drug resistance in cancer growth field. The chemotherapeutic specialists harm directly or indirectly the cancer cells DNA, in this way, there are systems that can fix the harm of DNA. For instance, platinum-based specialists, for example, cisplatin cause DNA harm which prompts the apoptosis of tumoral cells. These agents occurs by the DNA repair systems, including

nucleotide excision repair and homologous recombination repair. These agents dependent on restraint of the DNA repair in the cancer cells (Borst P, 2009). The inhibition of DNA repair sensitize the disease cells to these drug and subsequently effective of the chemotherapy will increase. The imperfections in the DNA repair in the damage cells could be one of the helpful targets which can be conceivable by mutation (de Pagter MS, 2015).

## Gene amplification

Gene amplification is a mechanism of the drug resistance in 10% of the cancers, especially in leukemias. Expanding the quantities of target qualities by the quality enhancement in some tumoral cells, including leukemia influence the medication protection from Methotrexate (Woolley PV, 2013). The disease cells cause the drug resistance through giving the various duplicates of the Dihydrofolate reductase quality. The gene amplification increases the copy numbers of the oncogenes per cells to several hundred folds. This mechanism cause to the production of larger amounts of the related oncoproteins (Matsui A, 2013).

### **Disease and drug resistance mechanisms and pathways interruption**

<b>Disease</b>	<b>Drug resistance Mechanism and pathways interruption</b>	<b>References</b>
CML	Resistance to imatinib BCR-ABL Mutations (9; 22) t (22)	<a href="#">21,38</a>
Myeloproliferative disorders	JAK2	<a href="#">41</a>
AML	GSK-3b activity adhesion and Wnt-pathway b-catenin expression SHIP mutations PI3-kinase/Akt activation	<a href="#">42-44</a>
ALL	Increased Akt expression Regulation protein-1 and PI3K signaling PTEN mutation/deletion/inactivation	<a href="#">45,46</a>
Other human neoplasia	involvement of the Ras/Raf/MEK/ERK, PI3K/ PTEN/Akt and Jak/STAT cascades AKT/PKB signaling Raf/MEK/ERK pathway PTEN	<a href="#">1,46,47</a>

Table 1: Disease and drug resistance mechanisms and pathway interruption

## Epigenetic altering caused drug resistance

One of the important mechanisms of the drug resistance in the cancer therapy is the epigenetic altering. There are two types of the epigenetic altering such as 1. methylation of DNA and 2. histone alterations. The DNA methylation is a major epigenetic phenomenon. However, the methylation can occur throughout the genome in other positions (Pui CH, 2015). Acetylation and deacetylation of the specific lysine located at the terminal ends of histones and non-histone proteins performed by histone acetyltransferases (HATs) and histone deacetylases (HDACs) enzymes respectively. These enzymes alter the structure and composition of chromatin. The acetylation of lysine open the chromatin structure, and deacetylation of this unit cause the chromatin compaction and the stability of them, these mechanisms regulate the gene expression (Holohan C, 2013). For example, the tumor suppressor genes often silenced by methylation, in contrast, the hyper-methylation of oncogenes induced their expression. Demethylation of multi-drug resistance gene (MDR1), in the cancer cell lines, leads to the securing of multi drug-resistant phenotype and reduces the accumulation of the anti-tumor drug inside the cancer cells. MDR1 is overexpressed in the premature myeloid cancer cells, but the mature myeloid cancer cells decrease the expression of MDR1 (Wojtuszkiewicz A, 2015). The epigenetic mechanism can also influence their DNA repair system. In the mismatch repair system a few proteins includes such as hMLH1, hMSH1 and etc. The transformations or hypermethylation in the advertiser of following qualities cause malignancy. For instance, the change or hypermethylation of hMLH1 quality can cause the colorectal disease. So the combination of epigenetic and conventional chemotherapeutic agents are effective in the treatment of resisted tumors and cancerous cells (Smith CE, 2015).

## MicroRNA in drug resistance

miRNAs are ~22 nucleotide RNAs prepared from RNA hairpin structures. MiRNAs are very short to code for protein and play important roles in regulating gene expression. They manage most protein-coding qualities, remembering significant qualities for malignancy and particularly in disease drug obstruction age. There are three mechanisms involved in gene silencing with miRNA process: 1) Cleavage of the mRNA strand into two pieces, 2) Destabilization of the mRNA through shortening of its poly(A) tail and, 3) Less productive interpretation of the mRNA into proteins by ribosomes (Feng R, 2015).

miRNA profiling confirmed that these little particles assume a significant part in the advancement of chemosensitivity in various kinds of malignancy (Table 2) (Zhu X, 2014) (Shen X, 2016). miRNA may include in all the medication opposition components which referenced previously. miRNAs could expand the viability of tumors to chemotherapy specialist or it could keep away from cancer drug resistance. Additionally, these small molecules could prognosis and survival in response to chemotherapy.

## MECHANISMS

Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, characterized as (1) change of medication targets, (2) articulation of medication siphons, (3) articulation of detoxification systems, (4) decreased weakness to apoptosis, (5) expanded capacity to fix DNA harm, and (6) adjusted expansion. That adjustments of stroma and tumor microenvironment can contribute to the development of resistance. Cancer cells can and do utilize a few of these components all at one time, and there is extensive heterogeneity between tumors, requiring an individualized way to deal with disease treatment. As tumors are heterogeneous, positive determination of a drug resistance populace could help drive resistance.

## Mechanism action for Anti cancer drug-resistance

1. Alteration of Drug Targets: It is isolated drugs used in chemotherapy from newer agents targeting molecular pathways, that all drugs have targets. These targets can be adjusted by cells in various manners. Rapid down-regulation of a target gene expression is an obvious ploy, exemplified by the effect of doxorubicin on topoisomerase II $\alpha$  (F, 2005), however more alterations change of drug target by mutation is particularly in response of designated specialists, for example, receptor tyrosine kinase inhibitors (CR, 2005) (TJ, 2004).

### miRNAs involved in cancer drug resistance

miRNA	Target	Tumor	Chemotherapy agent
miR-7	MDR1	SCLC	Anthracyclines
miR-9	MDR1/ABCG2	Glioblastoma	Temozolomide
miR-17-5p	PTEN	Ovary	Paclitaxel
miR-21	PTEN, PDCD4	Breast	Trastuzumab
miR-25	ABCG2	Breast	Epirubicin
miR-103/107	P-gp	Gastric	Doxorubicin
miR-127	MDR1/MRP1	Glioma	Adriamycin
miR-129-5p	ABCB1	Gastric	Vincristinecisplatin 5-fluorouracil
miR-134	MRP1/ABCC1	Breast	Doxorubicin
miR-145	P-gp/ABCB1	Ovarian	Paclitaxel
miR-181a	PTEN	NSCLC	Paclitaxel, Cisplatin
miR-196a	MDR1/MRP1	NSCLC	Cisplatin
miR-200c	P-gp/ABCB1	Colorectal	Vincristineoxaliplatin cisplatin 5-fluorouracil mitomycin C
miR-202	BAFF	Multiple myeloma	Bortezomib, Thalidomide, Dexamethasone

Table 2: miRNAs involved in cancer drug resistance

2. Expression of drug efflux pumps : The ATP-restricting tape (ABC) proteins incorporates various membrane proteins ready to move a wide variety of substrates. Other than a capacity to move of poisons out of cells, different substrates incorporate amino acids, peptides, sugars, lipids, steroids, bile salts, nucleotides and endogenous metabolites. These siphons act to ensure cells by launching a wide assortment of poisons (Vasiliou V, 2009). These pumps act to protect cells by ejecting a wide

variety of toxins. In bacteria this toxin might be an antibiotic, in human cancer it is often an anticancer drug. Drug obstruction is interceded by the MDR1 (ABCB1) quality, which encodes a film based xenobiotic siphon atom, known as phenolic glycoprotein. Metabolite and nucleotide pumps have been discovered to be of significance, and qualities, for example, hENT1 have been accounted for to be significant mediators of chemo sensitivity in quality articulation contemplates (Parker KA, 2010) (Glaysher S, 2009). Rapid up-guideline of drug pimps can happen in cancer cells and lead to resistance (F, 2005).

3. Expression of detoxification mechanisms : Drug metabolism happens at the host level, where it underlies the pharmacokinetics of numerous medications, and within cancer cells themselves, where there might be significant heterogeneity. For example, glutathione S-transferase (GST $\pi$ ) are notable to be up-regulated in certain tumors and an expected reason for obstruction (Satta T, 1992). It is conceivable that formation and discharge of medications at the luminal surface of some all around separated adenocarcinomas may clarify the connection among separation and medication affectability to certain medications, however this remaining parts questionable (S., 2015). Modified local drug digestion and detoxification are key obstruction instruments across numerous malignancies. For instance, these cycles have been explored in the plasma cell malignant growth, Multiple Myeloma (MM), where a majority of patients repeatedly relapse and finally succumb to the disease (Hassen W, 2015). The dexprestion of 350 qualities encoding for take-up transporters, xenobiotic receptors, stage I and II medication using chemicals and efflux carriers was evaluated in MM cells of recently analyzed patients.
4. Reduced susceptibility to apoptosis and cell death : Apoptosis was recognised as a one of a kind type of cell death by Currie and others during the 1970s (Wyllie AH, 1980). That obviously avoidance of apoptosis supported the improvement of cancer cell and was a significant opposition system for disease cells to both chemotherapy (Makin G, 2001) and agents targeting signaling pathways (Glaysher S, 2014). Different types of cell demise may likewise be set off by against malignant growth drugs, including putrefaction, necroptosis, and autophagy (G, 2009). In all cases, the vital element in obstruction is by all accounts endurance flagging which forestalls cell demise. Not all forms of cell death are the same, and the level of damage required to achieve cell death is variable. Its importance in cancer treatment is controversial, but its induction may circumvent anti-apoptotic mechanisms.
5. Increased ability to repair DNA damage : As cancer should get permanent genomic transformations, cancer be seen as an illness of DNA repair as changes in these qualities produce the mutator phenotype fundamental the for the obtaining of additional transformations. When a change is gained tumors frequently become dependent on an alternate DNA fix pathway. A genuine illustration of this is exemplified by BRCA1/2. As BRACA1/2 are key parts of a DNA twofold strand fix pathway these tumors become subject to another DNA fix segment, PARP1, for replication fork movement (Tewari KS, 2015). Inhibition of PARP1 in these cancer cells is catastrophic and results in their death. This is the concept of synthetic lethality (Liu FW, 2016) and proposed as a potential weak spot in a cancer cell's defense. this concept enable the clinician to expand the remedial record among cancer and normal cells, it is normal that these methodologies will also have the potential to develop resistance. DNA damage is identify by cells, and they can't repair the harm, which is prompts apoptosis (Pflaum J, 2014).
6. Altered proliferation : The normal response to DNA damage that can't be repair is apoptosis, yet as Gerard Evan displayed in diploid fibroblasts, the limit for death is a lot higher in cells that are not developing (Harrington EA, 1994). Transient decrease in development is intervened partially by. Levels of P53 rise and from the start basically decrease cell cycle. only tipping over to stimulate apoptosis at a certain threshold (JM, 2014).




Figure 3:

We perceive six anti-cancer drug resistance. Cancer cells may alter drug targets by mutation or decreased expression; upregulate the expression of drug pump; increment the action of drug detoxification mechanisms; reduce their susceptibility to apoptosis; alter their level of proliferation; and increase their ability to repair DNA damage. These might be utilized without a moment's delay, yet there is significant heterogeneity between tumors, requiring an individualized way to deal with disease treatment.

## CONCLUSION

Cancer terms need to figure out how to play sub-atomic chess - effectively the cancer's reasonable reaction to any treatment used, and to be prepared for it. The devices given by the pharmaceutical industries to permit this have never been better, and combined with progressively modern radiotherapy and medical procedure, permit numerous patients to make due for quite a long time. An extraordinary arrangement is currently thought about instruments of medication opposition in disease cells.

The advancement of new designated anticancer treatments, development of new targeted anticancer therapies, mechanisms that have evolved in mammals to protect cells against cytotoxic compounds in the environment will continue to act as obstacles to successful treatment of cancer. Additional knowledge about these mechanisms of cancer drug resistance may help to design strategies to circumvent resistance and new drugs that are less susceptible to known resistance mechanisms. The principles of drug resistance or perhaps the rules of molecular chess – are increasingly clear and can improve patient care. The foundation of in vitro models that look like the multifactorial resistance measure saw in vivo is crucial, and drug-resistance cell lines, great models for understanding the resistance process in tumor cells and, thusly, for screening new drugs, to delineate the components of resistance found in the clinical context.

## ABBREVIATIONS

ABC          ATP-binding cassette

<b>ABCB1</b>	ATP binding cassette subfamily B member 1
<b>ALK</b>	Anaplastic lymphoma receptor tyrosine kinase
<b>ATP</b>	Adenosine triphosphate
<b>BCRP</b>	Breast cancer related protein (ABCG2)
<b>BRAF</b>	B-Raf proto-oncogene, serine/threonine kinase
<b>BRCA</b>	BRCA, DNA repair associated
<b>CSC</b>	Cancer stem cell
<b>GST<math>\pi</math></b>	Gluthathione S-transferase
<b>DNA</b>	Dexoxyribose nucleic acid
<b>EGFR</b>	Epidermal Growth Factor Receptor
<b>MDR</b>	Multidrug resistance (MDR)
<b>MM</b>	Multiple Myeloma
<b>MRP1</b>	Multidrug resistance related protein (ABCC1)
<b>Nrf2</b>	Nf-E2 related factor 2
<b>P12</b>	Tumor protein p12
<b>PARP1</b>	Poly(ADP-ribose) polymerase

## REFERENCE

1. **Longley DB, Johnston PG.** *Molecular mechanisms of drug resistanc.* 2005.
2. **Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT.** *Nitrogen mustard therapy: Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.* 1946.
3. —. *Nitrogen mustard therapy.* 1946.
4. **Nabholtz JM, Slamon D.** *New adjuvant strategies for breast cancer.* 2001.
5. **RJ, Kreitman.** *Immunotoxins for targeted cancer therapy.* 2006.
6. **RMP, Costa.** *Between parasitic theory and experimental oncology.* 1889-1945.
7. **Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA.** *Application of high-throughput, molecular-targeted screening to anticancer drug discovery.* 2002.
8. **Curran EK, Godfrey J, Klines J.:** *Mechanisms of immune tolerance in leukemia and lymphoma.* 2017.
9. **neoplasms, Chauffaille MDLL: Myeloproliferative.** *a review of diagnostic criteria and clinical aspects.* 2016.
10. **McDermott M, Eustace A, Busschots S, Breen L, Clynes M, O'Donovan N, Stordal B.:** *In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines.* 2014.
11. **J., Zhao.** *Cancer stem cells and chemoresistance.* 2016.
12. **CH, Choi.** *ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.* 2005.

13. **Shi Z, Liang YJ, Chen ZS, Wang XH, Ding Y, Chen LM, Fu LW.** *Overexpression of survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.* 2007.
14. **Okamura T, Kikuchi T, Okada M, Wakizaka H, Zhang MR.** *Imaging of activity of multidrug resistance-associated protein 1 in the lungs.* 2013.
15. **SE, Benner.** *Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines.* 1991.
16. **VK, Arora.** *Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.* 2013.
17. **Gatenby RA, Gillies RJ, Brown JS.** *The evolutionary dynamics of cancer prevention.* 2010.
18. **Nathanson DA, Gini B, Mottahedeh J, Visnyei K.** *Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.* 2014.
19. **Junttila MR, de Sauvage FJ.** *Influence of tumour micro-environment heterogeneity on therapeutic response.* 2013.
20. **Pal B, Bayat-Mokhtari R, Li H, Bhuyan R, Talukdar J, Sandhya.** *Stem cell altruism may serve as a novel drug resistance mechanism in oral cancer.* 2016.
21. **J, Settleman.** *Cancer: Bet on drug resistance.* 2016.
22. **Dean M, Fojo T, Bates S.** *Tumour stem cells and drug resistance.* 2005.
23. **Michael M, Doherty MM.** *Tumoral drug metabolism.* 2005.
24. **Zahreddine H, Borden KL.** *Mechanisms and insights into drug resistance in cancer.* 2013.
25. **Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M. et al.** *Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.* 2006.
26. **Longo-Sorbello GS, Bertino JR.** *Current understanding of methotrexate pharmacology and efficacy in acute leukemias.* 2001.
27. **JM., Ribera.** *Acute lymphoblastic leukemia.* 2016.
28. **Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R. et al.** *Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: .* 2009.
29. **Simon JA, Kingston RE.** *Occupying chromatin.* 2013.
30. **S, Byler.** *Drug resistance in cancer: An overview.* 2014.
31. **Borst P.** *A family of drug transporters.* 2009.
32. **de Pagter MS, Kloosterman WP.** *The diverse effects of complex chromosome rearrangements and chromothripsis in cancer development.* 2015.

33. **Woolley PV, Tew KD.** *Mechanisms of drug resistance in neoplastic cells.* 2013.
34. **Matsui A, Ihara T, Suda H, Mikami H, Semba K.** *Gene amplification.* 2013.
35. **Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A.** *Childhood acute lymphoblastic leukemia.* 2015.
36. **Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG.** *Cancer drug resistance.* 2013.
37. **Wojtuszkiewicz A, Assaraf YG, Hoekstra M, Jansen G, Peters GJ, Sonneveld E.** *The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia.* 2015.
38. **Smith CE, Bowen N, Graham WJ Th, Goellner EM, Srivatsan A, Kolodner RD.** *Activation of saccharomyces cerevisiae Mlh1-Pms1 endonuclease in a Reconstituted Mismatch Repair System. J Biol Chem.* 2015.
39. **Feng R, Dong L.** *Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.* 2015.
40. **Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y.** *miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer.* 2014.
41. **Shen X, Guo Y, Qi J, Shi W, Wu X, Ni H.** *Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells.* 2016.
42. **F, Di Nicolantonio.** *Cancer cell adaptation to chemotherapy.* 2005.
43. **CR, Antonescu.** *Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.* 2005.
44. **TJ, Lynch.** *Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.* 2004.
45. **Vasiliou V, Vasiliou K, Nebert DW.** *Human ATP-binding cassette (ABC) transporter family.* 2009.
46. **Parker KA, et al.** *The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy.* 2010.
47. **Glaysheer S, et al.** *Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC).* 2009.
48. **F, Di Nicolantonio.** *Cancer cell adaptation to chemotherapy.* 2005.
49. **Satta T.**
50. —. *Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer.* 1992.
51. **S., Singh.** *Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death.* 2015.

52. **Hassen W, et al.** *Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget.* . 2015.
53. **Wyllie AH, Kerr JF, Currie AR.** *Cell death: the significance of apoptosis.* 1980.
54. **Makin G, Dive C.** *Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer.* 2001.
55. **Glaysheer S.** *Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.* 2014.
56. **G, Kroemer.** *Classification of cell death: recommendations of the Nomenclature Committee on Cell Death.* . 2009.
57. **Tewari KS, Eskander RN, Monk BJ.** *Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.* 2015.
58. **Liu FW, Tewari KS.** *New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.* 2016.
59. **Pflaum J, Schlosser S, Muller M.** *p53 Family and Cellular Stress Responses in Cancer.* 2014.
60. **Harrington EA.** *c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines.* 1994.
61. **JM, Beckta.** *Revisiting p53 for cancer-specific chemo- and radiotherap.* 2014.

